跳至主要内容
临床试验/NL-OMON55130
NL-OMON55130招募中不适用

Efficacy of Spinal Cord Stimulation in patients with Refractory Angina Pectoris; a randomized controlled trial - SCRAP trial

Catharina-ziekenhuis0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Refractory Angina Pectoris: - Stable angina pectoris CCS class III or IV,
  • with a minimum of 5 episodes of angina pectoris over the course of one week,
  • during a minimum period of three months prior to screening; - Coronary
  • angiogram (CAG) performed within the last 12 months showing significant
  • coronary artery disease defined as at least one coronary artery stenosis of
  • >75% or 50 - 75% with proven ischaemia (see below), not suitable for
  • revascularisation. Confirmed by one (or two in case of doubt) interventional
  • cardiologist based on CAG images; - Optimal anti-anginal medication. Patients
  • should at least use; b-blocker and/or calcium channel blocker, short- and/or
  • long-acting nitrate. If the patient doesn*t use one of these groups of
  • medication the reason (side-effects) should be clear.
  • - Proven ischemia: - MIBI-SPECT: summed stress score (SSS) of at least 1, in
  • combination with summed difference score (SDS) of at least 1 (1-4 mild
  • ischaemia, > 4 moderate to severe ischaemia); - FFR: < 0.80, with no
  • intervention options (determined by intervention cardiologist); - MRI
  • perfusion: >= 1 segment of subendocardial hypoperfusion during stress perfusion,
  • not present at rest and no matching fibrosis (using 16 segment AHA heart
  • model); - PET: Semi-quantitative measurement: SSS score of at least 1, in
  • combination with SDS score of at least 1 (1-4 mild ischaemia, > 4 moderate to
  • severe ischaemia). Quantitative measurement: reduced myocardial perfusion
  • - No revascularisation (PCI and/or CABG) performed between ischaemia testing
  • and study inclusion.
  • - Age 18 years or older

排除标准

  • - Acute coronary syndrome (ACS) during three month period prior to screening
  • - Life expectancy less than 12 months
  • - Inability to perform a 6-minute walking test
  • - Inability to give informed consent
  • - No proven ischemia (see Inclusion criteria for definition)
  • - Spinal cord disease which could prevent correct positioning of the lead in
  • the epidural space; to be determined by the anaesthesiologist performing the
  • implantation
  • - Anticoagulation therapy that cannot be stopped prior to spinal cord
  • stimulator implantation
  • - Inadequate paresthesia coverage, during implantation, of the thoracic region
  • where angina complaints are localized
  • - Pregnancy
  • - Mild Cognitive Impairment or dementia
  • - Concomitant symptomatic valvular heart disease including severe aortic
  • stenosis and/or regurgitation, severe mitral valve stenosis and/or
  • regurgitation or severe tricuspid valve regurgitation.

研究者

相似试验